Erasca, Inc. (NASDAQ:ERAS - Get Free Report) traded up 5.4% during mid-day trading on Thursday. The stock traded as high as $14.54 and last traded at $14.5070. 2,064,523 shares were traded during mid-day trading, a decline of 65% from the average daily volume of 5,839,608 shares. The stock had previously closed at $13.76.
Analyst Ratings Changes
Several equities research analysts have issued reports on the stock. Guggenheim lifted their target price on shares of Erasca from $20.00 to $21.00 and gave the company a "buy" rating in a research report on Thursday, August 13th. Bank of America increased their price target on shares of Erasca from $18.00 to $20.00 and gave the stock a "neutral" rating in a report on Friday, August 14th. Leerink Partners started coverage on shares of Erasca in a report on Tuesday. They set an "outperform" rating and a $35.00 price objective for the company. Weiss Ratings reiterated a "sell (d-)" rating on shares of Erasca in a research report on Tuesday, September 8th. Finally, HC Wainwright increased their target price on Erasca from $18.00 to $22.00 and gave the company a "buy" rating in a research note on Wednesday, August 12th. Nine equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, Erasca has a consensus rating of "Moderate Buy" and a consensus target price of $23.17.
Check Out Our Latest Report on ERAS
Erasca Price Performance
The stock's 50 day simple moving average is $14.85 and its two-hundred day simple moving average is $15.32. The firm has a market cap of $5.00 billion, a P/E ratio of -14.33 and a beta of 0.68.
Erasca (NASDAQ:ERAS - Get Free Report) last announced its quarterly earnings results on Thursday, November 12th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.02). Equities research analysts anticipate that Erasca, Inc. will post -0.51 earnings per share for the current year.
Institutional Investors Weigh In On Erasca
Institutional investors and hedge funds have recently bought and sold shares of the business. Frazier Life Sciences Management L.P. lifted its position in shares of Erasca by 1.2% in the second quarter. Frazier Life Sciences Management L.P. now owns 24,975,188 shares of the company's stock worth $457,545,000 after buying an additional 300,000 shares in the last quarter. BlackRock Inc. bought a new stake in Erasca in the second quarter worth $387,544,000. Vivo Capital LLC increased its position in Erasca by 31.0% in the first quarter. Vivo Capital LLC now owns 12,151,480 shares of the company's stock worth $196,611,000 after purchasing an additional 2,878,052 shares during the last quarter. Siren L.L.C. raised its stake in Erasca by 28.4% during the first quarter. Siren L.L.C. now owns 11,244,246 shares of the company's stock valued at $181,932,000 after purchasing an additional 2,486,997 shares in the last quarter. Finally, ARCH Venture Management LLC purchased a new stake in Erasca during the second quarter valued at $129,917,324. 67.78% of the stock is owned by institutional investors.
About Erasca
(
Get Free Report)
Erasca, Inc. is a clinical-stage biotechnology company focused on developing medicines for cancer. Its research centers on the RAS/MAPK signaling pathway, which is involved in the growth of many tumors and can be difficult to target with existing therapies. The company's pipeline includes investigational drug candidates designed to inhibit RAS proteins and other targets in the pathway. Erasca evaluates these candidates for potential use across multiple cancer types; its medicines remain in development rather than being marketed as approved treatments.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Erasca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Erasca wasn't on the list.
While Erasca currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.